Genetic comorbidity of depression and somatic disorders

Rukavishnikov G.V.; Kibitov A.O.; Mazo G.; Neznanov N.G.

doi:https://doi.org/10.17116/jnevro201911901189

Close metadata

Recommended articles:

The relationship between inflammatory markers, fatigue, and effort-based decision-making in patients at clinical high risk for psychosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):85-91

The gut microbiota in bipolar disorder. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):28-33

Comorbidity of depression and dementia: epidemiological, biological and therapeutic aspects. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):113-121

Online phenotypes of depression symptoms are associated with polygenic risk scores of somatic diseases in a population-based cohort. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):122-131

Perioperative prevention of bleeding in glaucoma surgery. Russian Annals of Ophthalmology. 2024;(5):118-124

Efficacy of alpha-glutamyl-tryptophan in the treatment of chronic atrophic gastritis: case series. Russian Journal of Evidence-Based Gastroenterology. 2024;(4):121-128

Association between the vitamin D level and depression in the elderly people in the European North of Russia. Russian Journal of Preventive Medicine. 2024;(12):107-113

Neuropeptide Y and inflammatory indices in women after repeated cesarean section. Russian Bulletin of Obstetrician-Gynecologist. 2024;(6):35-40

Atopic dermatitis and skin toxic reactions: comparative characteristics, psychosomatic aspects and patient management tactics. Russian Journal of Clinical Dermatology and Venereology. 2024;(6):744-752

Antifungal immunity in patients with chronic rhinosinusitis with nasal polyps. Russian Bulletin of Otorhinolaryngology. 2024;(6):40-45

Abstract:

The aim of our review was to evaluate the perspectives of new therapeutic approaches in comorbid depressive and somatic disorders based on common pathological mechanisms and their genetic risk factors. Literature analysis showed that depression was a complex heterogeneous condition associated with significant prevalence of metabolic, cardiovascular and immune disturbances. The understanding of common molecular mechanisms of risks and course of abovementioned disorders could provide a new strategy for early diagnosis and therapeutic optimization and give the opportunity of «targeted» approach to different pathological elements.

Keywords:

depression

chronic somatic disorders

genetic comorbidity

clusters of genetic risks

inflammation

Authors:

Rukavishnikov G.V.

Bekhterev National Medical Research Center of Psychiatry and Neurology, St-Petersburg, Russia

Kibitov A.O.

Laboratoriia molekuliarnoĭ genetiki Natsional'nogo nauchnogo tsentra narkologii, Moskva

Mazo G.

Sankt-Peterburgskiĭ nauchno-issledovatel'skiĭ psikhonevrologicheskiĭ institut im. V.M. Bekhtereva;
Sankt-Peterburgskiĭ gosudarstvennyĭ universitet, Sankt-Peterburg

Neznanov N.G.

Sankt-Peterburgskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. I.P. Pavlova;
Sankt-Peterburgskiĭ nauchno-issledovatel'skiĭ psikhonevrologicheskiĭ institut im. V.M. Bekhtereva;
fakul'tet psikhiatrii Universiteta shtata Pensil'vaniia (SShA)

ORCID: 0000-0001-5618-4206

Close metadata

References:

Neznanov NG, Mazo GE, Rukavishnikov GV, Kibitov AO. Depression as a predictor of somatic disorders: pathological premises and genetic risks. Uspehi Fiziologicheskih Nauk. 2017;48(4):29-39. (In Russ.)
Neznanov NG, Kozlova SN, Mazo GE, Shlyakhto EV, Smirnov BI. Comorbidity of depressive disorders and coronary heart disease: general aspects of pathogenesis. Zhurnal Nevrologii i Psihiatrii im. S.S. Korsakova. 2015;(5):20-26. (In Russ.) https://doi.org/10.17116/jnevro20151155120-26
Van der Kooy K, van Hout H, Marwijk H, Marten H, Stehouwer C, Beekman A. Depression and the risk for cardiovascular diseases: systematic review and meta-analysis. Int J Geriatr Psychiatry. 2007;22:613-626. https://doi.org/10.1002/gps.1723
Nouwen A, Lloyd CE, Pouwer F. Depression and type 2 diabetes over the lifespan: a meta-analysis. Diabetes Care. 2009;32:56-57. https://doi.org/10.2337/dc09-0179
Penninx BW, Guralnik JM, Pahor M, Ferrucci L, Cerhan JR, Wallace RB, Havlik RJ. Chronically depressed mood and cancer risk in older persons. J Natl Cancer Inst. 1998;90:1888-1893. https://doi.org/10.1093/jnci/90.24.1888
World Health Organization. The World Health Report 2001. Mental Health: New understanding. Geneve, WHO; 2001.
Lesperance F, Frasure-Smith N. Depression in patients with cardiac disease: a practical review. J Psychosom Res. 2000;48:379-391. https://doi.org/10.1016/s0022-3999(99)00102-6
Mazo GE, Neznanov NG. Terapevticheski rezistentnye depressii. 2d edition. SPb.: Ladoga; 2013. (In Russ.)
Srivastava I, Thukral N, Hasija Y. Genetics of human age related disorders. Adv Gerontol. 2015;28(2):228-247.
Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol. 2016;16:22-34. https://doi.org/10.1038/nri.2015.5
Kalkman HO, Feuerbach D. Antidepressant therapies inhibit inflammation and microglial M1-polarization. Pharmacol Ther. 2016;163:82-93. https://doi.org/10.1016/j.pharmthera.2016.04.001
Kibitov AO. Biopsihosocial’naja model’ jetiopatogeneza psihicheskih zabolevanij: kriticheskaja rol’ geneticheskih faktorov. Biomarkery v psihiatrii: poisk i perspektivy. Tomsk. 2016. (In Russ.)
Pourcain B, Haworth C, Davis O. Heritability and genome-wide analyses of problematic peer relationships during childhood and adolescence. Hum Genet. 2014;134(6):539-551. https://doi.org/10.1007/s00439-014-1514-5
Lang UE, Borgwardt S. Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies. Cell Physiol Biochem. 2013;31:761-777. https://doi.org/10.1159/000350094
Alhajji L, Nemeroff C. Personalized Medicine and Mood Disorders. Psychiatric Clinics of North America. 2015;38(3):395-403. https://doi.org/10.1016/j.psc.2015.05.003
Arreola R, Becerril-Villanueva E, Cruz-Fuentes C, Velasco-Velázquez MA, Garcés-Alvarez ME, Hurtado-Alvarado G, Quintero-Fabian S, Pavón L. Immunomodulatory effects mediated by serotonin. J Immunol Res. 2015; 2015:354957. https://doi.org/10.1155/2015/354957
Eyre H, Lavretsky H, Kartika J, Qassim A, Baune BT. Modulatory Effects of Antidepressant Classes on the Innate and Adaptive Immune System in Depression. Pharmacopsychiatry. 2016;49(3):85-96. https://doi.org/10.1055/s-0042-103159
Nemeroff CB, Goldschmidt-Clermont PJ. Heartache and heartbreak-the link between depression and cardiovascular disease. Nat Rev Cardiol. 2012;9:526-539. https://doi.org/10.1038/nrcardio.2012.91
Chrapko WE, Jurasz P, Radomski MW, Lara N, Archer SL, Le Mellédo JM. Decreased platelet nitric oxide synthase activity and plasma nitric oxide metabolites in major depressive disorder. Biol Psychiatry. 2004;56:129-134. https://doi.org/10.1016/j.biopsych.2004.03.003
Xiong GL, Prybol K, Boyle SH, Hall R, Streilein RD, Steffens DC, Krishnan R, Rogers JG, O’Connor CM, Jiang W. SADHART-CHF Investigators. SADHART-CHF Investigators: Inflammation Markers and Major Depressive Disorder in Patients With Chronic Heart Failure: Results From the Sertraline Against Depression and Heart Disease in Chronic Heart Failure Study. Psychosom Med. 2015;77:808-815. https://doi.org/10.1097/psy.0000000000000216
Warner-Schmidt JL, Duman RS. VEGF is an essential mediator of the neurogenic and behavioral actions of antidepressants. Proc Natl Acad Sci USA. 2007;104:4647-4652. https://doi.org/10.1073/pnas.0610282104
Martiny K. Novel Augmentation Strategies in Major Depression. Dan Med J. 2017;64(4). pii: B5338. https://doi.org/10.1159/000061657
Zanardi R, Serretti A, Rossini D, Franchini L, Cusin C, Lattuada E, Dotoli D, Smeraldi E. Factors affecting fluvoxamine anti-depressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biol Psychiatry. 2001;50:323-330. https://doi.org/10.1016/s0006-3223(01)01118-0
Stafford L, Berk M. The use of statins after a cardiac intervention is associated with reduced risk of subsequent depression: proof of concept for the inflammatory and oxidative hypotheses of depression? J Clin Psychiatry. 2011;72:1229-1235. https://doi.org/10.4088/jcp.09m05825blu
Wexler DJ, Porneala B, Chang Y, Huang ES, Huffman JC, Grant RW. Diabetes differentially affects depression and self-rated health by age in the US. Diabetes Care. 2012;35:1575-1577. https://doi.org/10.2337/dc11-2266
Nouwen A, Lloyd C., Pouwer F. Depression and type 2 diabetes over the lifespan: a meta-analysis. Diabetes Care. 2009;32:56-57. https://doi.org/10.2337/dc09-0179
Cline BH, Steinbusch HW, Malin D, Revishchin AV, Pavlova GV, Cespuglio R, Strekalova T. The neuronal insulin sensitizer dicholine succinate reduces stress-induced depressive traits and memory deficit: possible role of insulin-like growth factor 2. BMC Neurosci. 2012;13:110. https://doi.org/10.1186/1471-2202-13-11
Kleinridders A, Cai W, Cappellucci L, Ghazarian A, Collins WR, Vienberg SG, Pothos EN, Kahn CR. Insulin resistance in brain alters dopamine turnover and causes behavioral disorders. Proc Natl Acad Sci USA. 2015;112:3463-3468. https://doi.org/10.1073/pnas.1500877112
Roopan S, Larsen ER. Use of antidepressants in patients with depression and comorbid diabetes mellitus: a systematic review. Acta Neuropsychiatr. 2016;25:1-13. https://doi.org/10.1017/neu.2016.54
Colle R, de Larminat D, Rotenberg S, Hozer F, Hardy P, Verstuyft C, Fève B, Corruble E. Pioglitazone could induce remission in major depression: a meta-analysis. Neuropsychiatr Dis Treat. 2016;13:9-16. https://doi.org/10.2147/ndt.s121149
Kashani L, Omidvar T, Farazmand B, Modabbernia A, Ramzanzadeh F, Tehraninejad ES, Ashrafi M, Tabrizi M, Akhondzadeh S. Does pioglitazone improve depression through insulin-sensitization? Results of a randomized double-blind metformin-controlled trial in patients with polycystic ovarian syndrome and comorbid depression. Psychoneuroendocrinology. 2013;38:767-776. https://doi.org/10.1016/j.psyneuen.2012.08.010
Sun Y, Vedsted P, Fenger-Grøn M, Wu CS, Bech BH, Olsen J, Benros ME, Vestergaard M. Cancer Mortality in People Treated with Antidepressants before Cancer Diagnosis: A Population Based Cohort Study. PLoS One. 2015; 10:e0138134. https://doi.org/10.1371/journal.pone.0138134
Engeli L, Delahaye M, Borgwardt S, Gallinat J, Muller D, Walter M, Lang UE, Beck J. Akt2 Gene is Associated with Anxiety and Neuroticism in Humans. J Vasc Med Surg. 2014;2:141. https://doi.org/10.4172/2329-6925.1000141
Lang UE, Heger J, Willbring M, Domula M, Matschke K, Tugtekin SM. Immunosuppression using the mammalian target of rapamycin (mTOR) inhibitor everolimus: pilot study shows significant cognitive and affective improvement. Transplant Proc. 2009;41:4285-4288. https://doi.org/10.1016/j.transproceed.2009.08.050
Bongiorno-Borbone L, Giacobbe A, Compagnone M, Eramo A, De Maria R, Peschiaroli A, Melino G. Antitumoral effect of desmethylclomipramine in lung cancer stem cells. Oncotarget. 2015;6:16926-16938. https://doi.org/10.18632/oncotarget.4700
Uzawa K, Kasamatsu A, Shimizu T, Saito Y, Saito Y, Baba T, Sakuma K, Fushimi K, Sakamoto Y, Ogawara K, Shiiba M, Tanzawa H. Suppression of metastasis by mirtazapine via restoration of the Lin-7C/β-catenin pathway in human cancer cells. Sci Rep. 2014;4:5433. https://doi.org/10.1038/srep05433
Walker AJ, Card T, Bates TE, Muir K. Tricyclic antidepressants and the incidence of certain cancers: a study using the GPRD. British Journal of Cancer. 2011;104:193-197. https://doi.org/10.1038/sj.bjc.6605996
Pottegård A, García Rodríguez LA, Rasmussen L, Damkier P, Friis S, Gaist D. Use of tricyclic antidepressants and risk of glioma: a nationwide case-control study. Br J Cancer. 2016;114:1265-1268. https://doi.org/10.1038/bjc.2016.109
Zhang Z, Du X, Zhao C, Cao B, Zhao Y, Mao X. The antidepressant amitriptyline shows potent therapeutic activity against multiple myeloma. Anticancer Drugs. 2013;24:792-798. https://doi.org/10.1097/cad.0b013e3283628c21
Yuan SY, Cheng CL, Ho HC, Wang SS, Chiu KY, Su CK, Ou YC, Lin CC. Nortriptyline induces mitochondria and death receptor-mediated apoptosis in bladder cancer cells and inhibits bladder tumor growth in vivo. Eur J Pharmacol. 2015;761:309-320. https://doi.org/10.1016/j.ejphar.2015.06.007
Mun AR, Lee SJ, Kim GB, Kang HS, Kim JS, Kim SJ. Fluoxetine-induced apoptosis in hepatocellular carcinoma cells. Anticancer Res. 2013;33:3691-3697. https://doi.org/10.1515/cmble-2015-0030
Zalli A, Jovanova O, Hoogendijk WJ, Tiemeier H, Carvalho LA. Low-grade inflammation predicts persistence of depressive symptoms. Psychopharmacology. 2016;233:1669-1678. https://doi.org/10.1007/s00213-015-3919-9
Kohler O, Benros ME, Nordentoft M, Farkouh ME, Iyengar R., Mors O, Krogh J. Effect of Anti-inflammatory Treatment on Depression, Depressive Symptoms, and Adverse Effects A Systematic Review and Metaanalysis of Randomized Clinical Trials. JAMA Psychiatry. 2014;71:1381-1391. https://doi.org/10.1001/jamapsychiatry.2014.1611
Hannestad J, Dellagioia N, Bloch M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology. 2011;36:2452-2459. https://doi.org/10.1038/npp.2011.132
Hernandez ME, Martinez-Fong D, Perez-Tapia M, Estrada-Garcia I, Estrada-Parra S, Pavón L. Evaluation of the effect of selective serotonin-reuptake inhibitors on lymphocyte subsets in patients with a major depressive disorder. Eur Neuropsychopharmacol. 2010;20:88-95. https://doi.org/10.1016/j.euroneuro.2009.11.005
Martino M, Rocchi G, Escelsior A, Fornaro M. Immunomodulation mechanism of antidepressants: interactions between serotonin/norepinephrine balance and Th1/Th2 Balance. Curr Neuropharmacol. 2012;10:97-123. https://doi.org/10.2174/157015912800604542
Piletz JE, Halaris A, Iqbal O, Fareed J, Zhu H, Sinacore J, Devane CL. Pro-inflammatory biomakers in depression: treatment with venlafaxine. World J Biol Psychiatry. 2009;10:313-323. https://doi.org/10.1080/15622970802573246
Fischer S, Macare C, Cleare AJ. Hypothalamic-pituitary-adrenal (HPA) axis functioning as predictor of antidepressant response — Meta-analysis. Neuroscience & Biobehavioral Reviews. 2017;83:200-211. https://doi.org/10.1016/j.neubiorev.2017.10.012
Müller B, Wilcke A, Boulesteix AL, Brauer J, Passarge E, Boltze J, Kirsten H. Improved prediction of complex diseases by common genetic markers: state of the art and further perspectives. Hum Genet. 2016;135(3):259-272. https://doi.org/10.1007/s00439-016-1636-z
Otanfio LM, Izquierdoa LB, Mondragón AG, Alonso Pinedo M, Querejeta Ayerdi I. After six months of anti-psychotic treatment: Is the improvement in mental health at the expense of physical health? Rev PsiquiatrSaludMent (Barc.). 2013;6(1):26-32. https://doi.org/10.1016/j.rpsmen.2012.04.010
Bak M, Fransen A, Janssen J, van Os J, Drukker M. Almost All Antipsychotics Result in Weight Gain: A Meta-Analysis. PLoS ONE. 2014;9:94-112. https://doi.org/10.1371/journal.pone.0094112
Srivastava I, Gahlot LK, Khurana P, Hasija Y. dbAARD & AGP: A computational pipeline for the prediction of genes associated with age related disorders. Journal of Biomedical Informatics. 2016;60:153-161. https://doi.org/10.1016/j.jbi.2016.01.004
Hollands GJ, French DP, Griffin SJ, Prevost AT, Sutton S, King S, Marteau TM. The impact of communicating genetic risks of disease on risk-reducing health behaviour: systematic review with meta-analysis. BMJ. 2016; 352:i1102. https://doi.org/10.1136/bmj.i1102
Baune BT, Stuart M, Gilmour A, Wersching H, Heindel W, Arolt V, Berger K. The relationship between subtypes of depression and cardiovascular disease: a systematic review of biological models. Transl Psychiatry. 2012; 2:e92. https://doi.org/10.1038/tp.2012.18
Neznanov NG, Mazo GE, Kozlova SN, Krizhanovsky AS. From the development of depression endophenomenological classification to differential antidepressant treatment. Sovremennaja Terapija Psihicheskih Rasstrojstv. 2013;4:1-7. (In Russ.)
Malhi G, Parker G, Greenwood J. Structural and functional models of depression: from sub — types to substrates. Acta Psychiatr Scand. 2005;111:94-105. https://doi.org/10.1111/j.1600-0447.2004.00475.x
Penninx BW, Milaneschi Y, Lamers F, Vogelzangs N. Understanding the somatic consequences of depression: biological mechanisms and the role of depression symptom profile. BMC Med. 2013;11:129. https://doi.org/10.1186/1741-7015-11-129
Milaneschi Y, Lamers F, Peyrot WJ, Abdellaoui A, Willemsen G, Hottenga JJ, Jansen R, Mbarek H, Dehghan A, Lu C. CHARGE inflammation working group, Boomsma D.I., Penninx B.W. Polygenic dissection of major depression clinical heterogeneity. Mol Psychiatry. 2016;21(4):516-522. https://doi.org/10.1038/mp.2015.86
Neznanov NG, Mazo GE, Kibitov AO, Gorobets LN. Atypical depression: from phenotype to endophenotype. Social’naja i Klinicheskaja Psihiatrija. 2016;26(3):5-16. (In Russ.)
Currier MB, Nemeroff CB. Depression as a risk factor for cancer: from pathophysiological advances to treatment implications. Annu Rev Med. 2014;65:203-221. https://doi.org/10.1146/annurev-med-061212-171507